Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study

(2021) Ludwig Kappos et al.   JAMA Neurology

Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson’s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model

(2020) Élise Pépin et al.   Frontiers in Pharmacology

Fingolimod inhibits multiple stages of the HIV-1 life cycle

(2020) Rachel S. Resop et al.   PLoS Pathogens

Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association?

(2020) Frédéric London et al.   Multiple Sclerosis and Related Disorders

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

(2020) Brian G Feagan et al.   Lancet Gastroenterology & Hepatology

P030 Ozanimod Efficacy, Safety, and Histology in Patients with Moderate-to-Severe Ulcerative Colitis During Maintenance in the Phase 3 True North Study

(2020) Danese Silvio et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study

(2019) G D’Haens et al.   Journal of Crohns & Colitis

Blockage of sphingosine‐1‐phosphate receptor 2 attenuates allergic asthma in mice

(2019) Soo‐Jin Park et al.   BRITISH JOURNAL OF PHARMACOLOGY

Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease

(2019) Isabel Carreras et al.   Scientific Reports

Sphingosine-1-Phosphate Receptor Modulator, FTY720, Improves Diastolic Dysfunction and Partially Reverses Atrial Remodeling in a Tm-E180G Mouse Model Linked to Hypertrophic Cardiomyopathy

(2019) David M. Ryba et al.   Circulation-Heart Failure

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis

(2019) William J. Sandborn et al.   GASTROENTEROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

(2019) Jeffrey A Cohen et al.   LANCET NEUROLOGY

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

(2019) Giancarlo Comi et al.   LANCET NEUROLOGY

Sphingolipid Metabolism Perturbations in Rett Syndrome

(2019) Cappuccio et al.   Metabolites

Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain

(2018) Katherine Stockstill et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial

(2018) Richard Hughes et al.   LANCET NEUROLOGY

Progressive multifocal leukoencephalopathy after fingolimod treatment

(2018) Joseph R. Berger et al.   NEUROLOGY

S1PR1 (Sphingosine-1-Phosphate Receptor 1) Signaling Regulates Blood Flow and PressureNovelty and Significance

(2017) Anna Cantalupo et al.   HYPERTENSION

Phase IIa trial of fingolimod for amyotrophic lateral sclerosis demonstrates acceptable acute safety and tolerability

(2017) James D. Berry et al.   MUSCLE & NERVE

Genome-wide in vivo screen identifies novel host regulators of metastatic colonization

(2017) Louise van der Weyden et al.   NATURE

FTY720/fingolimod, an oral S1PR modulator, mitigates radiation induced cognitive deficits

(2017) Alexander M. Stessin et al.   NEUROSCIENCE LETTERS

Size-selective opening of the blood–brain barrier by targeting endothelial sphingosine 1–phosphate receptor 1

(2017) Keisuke Yanagida et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

S1P1 deletion differentially affects TH17 and Regulatory T cells

(2017) Ahmet Eken et al.   Scientific Reports

FTY720 (Gilenya) treatment prevents spontaneous autoimmune myocarditis and dilated cardiomyopathy in transgenic HLA-DQ8-BALB/c mice

(2016) Ferenc Boldizsar et al.   CARDIOVASCULAR PATHOLOGY

Recent advances in the development of sphingosine kinase inhibitors

(2016) Melissa R. Pitman et al.   CELLULAR SIGNALLING

Characterization of white matter abnormalities in early-stage schizophrenia

(2016) Tom A. Hummer et al.   Early Intervention in Psychiatry

Modulating sphingosine 1-phosphate signaling with DOP or FTY720 alleviates vascular and immune defects in mouse sepsis

(2016) Nasr Y. A. Hemdan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

(2016) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy

(2016) Deron R. Herr et al.   Scientific Reports

Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic StrokeCLINICAL PERSPECTIVE

(2015) Zilong Zhu et al.   CIRCULATION

SEW2871 protects from experimental colitis through reduced epithelial cell apoptosis and improved barrier function in interleukin-10 gene-deficient mice

(2015) Jianning Dong et al.   IMMUNOLOGIC RESEARCH

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

Effects of Topical Sphingosine-1-Phosphate 1 Receptor Agonist on Corneal Allograft in Mice

(2014) Liang Jia et al.   CORNEA

Enhanced sphingosine-1-phosphate receptor 2 expression underlies female CNS autoimmunity susceptibility

(2014) Lillian Cruz-Orengo et al.   JOURNAL OF CLINICAL INVESTIGATION

Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial

(2014) Andrea Vaclavkova et al.   LANCET

Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study

(2014) Nele Claes et al.   PLoS One

Protection of ferrets from pulmonary injury due to H1N1 2009 influenza virus infection: Immunopathology tractable by sphingosine-1-phosphate 1 receptor agonist therapy

(2014) John R. Teijaro et al.   VIROLOGY

Fingolimod for the Treatment of Intracerebral Hemorrhage

(2014) Ying Fu et al.   JAMA Neurology

FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease

(2013) Alba Di Pardo et al.   HUMAN MOLECULAR GENETICS

Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis

(2013) Katrin Schaper et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

S1P1localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity

(2013) David C. Montrose et al.   JOURNAL OF LIPID RESEARCH

Sphingosine-1-Phosphate-Induced Nociceptor Excitation and Ongoing Pain Behavior in Mice and Humans Is Largely Mediated by S1P3 Receptor

(2013) M. Camprubi-Robles et al.   JOURNAL OF NEUROSCIENCE

Flow-Regulated Endothelial S1P Receptor-1 Signaling Sustains Vascular Development

(2012) Bongnam Jung et al.   DEVELOPMENTAL CELL

Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival

(2012) Jenny S. Henkel et al.   EMBO Molecular Medicine

Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis

(2012) Suriyan Ponnusamy et al.   EMBO Molecular Medicine

Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage

(2012) William B. Rolland et al.   EXPERIMENTAL NEUROLOGY

Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma

(2012) A. Estrada-Bernal et al.   NEURO-ONCOLOGY

Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome

(2012) R. Deogracias et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oral therapy for type 1 diabetes mellitus using a novel immunomodulator, FTY720 (fingolimod), in combination with sitagliptin, a dipeptidyl peptidase-4 inhibitor, examined in non-obese diabetic mice

(2012) Takumi Tsuji et al.   Journal of Diabetes Investigation

Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis

(2011) David R. Beers et al.   BRAIN

Endothelial Cells Are Central Orchestrators of Cytokine Amplification during Influenza Virus Infection

(2011) John R. Teijaro et al.   CELL

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study

(2011) Andries J. Hoitsma et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice

(2010) Seiichiro Ando et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice

(2010) Tongsen Zheng et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

(2010) J. W. Choi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Sphingosine 1-Phosphate Receptor Signaling

(2009) Hugh Rosen et al.   Annual Review of Biochemistry

T-bet–dependent S1P5expression in NK cells promotes egress from lymph nodes and bone marrow

(2009) Craig N. Jenne et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment with Immunosuppressants FTY720 and Tacrolimus Promotes Functional Recovery after Spinal Cord Injury in Rats

(2009) Jie Zhang et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE